SEDLAŘÍKOVÁ, Lenka, Lenka KUBICZKOVÁ, Sabina ŠEVČÍKOVÁ and Roman HÁJEK. Mechanism of immunomodulatory drugs in multiple myeloma. Leukemia Research. 2012, vol. 36, No 10, p. 1218–1224. ISSN 0145-2126. doi:10.1016/j.leukres.2012.05.010.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Mechanism of immunomodulatory drugs in multiple myeloma
Authors SEDLAŘÍKOVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Lenka KUBICZKOVÁ (203 Czech Republic, belonging to the institution), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution) and Roman HÁJEK (203 Czech Republic, belonging to the institution).
Edition Leukemia Research, 2012, 0145-2126.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.764
RIV identification code RIV/00216224:14110/12:00057538
Organization unit Faculty of Medicine
UT WoS 000308044100002
Keywords in English Multiple myeloma; Treatment; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 28. 11. 2012 13:58.
Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition.
GAP304/10/1395, research and development projectName: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií
Investor: Czech Science Foundation
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NT11154, research and development projectName: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu
Investor: Ministry of Health of the CR
PrintDisplayed: 25. 3. 2023 22:02